Synthetic Design Lab Unveils First Advanced Logic-Gated ADC at AACR 2026, Achieving ≥10X Improvement in Targeted Cancer Cell Killing
Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) and protein engineering company, presented preclinical data in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrating that its proprietary SYNTHBODY™ therapeutic platform delivers log-order improvements in internalization, potency, and efficacy compared to current ADCs. The presentation marks the company's first public disclosure of platform and lead candidate data and introduces a new paradigm for ADC and biologic therapy design.
Synthetic Design Lab Emerges with $20M to Advance Next-Generation ADCs
Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) company advancing its novel SYNTHBODY therapeutic platform against a range of cancer indications, emerged from stealth today with $20 million in seed financing. Backed by multiple investors including Playground Global and Godfrey Capital, the company is focused on moving its first therapeutic into clinical trials next year.
